Review
doi: 10.1177/0961203312469692.
Epratuzumab for systemic lupus erythematosus
Affiliations
- PMID: 23553783
- DOI: 10.1177/0961203312469692
Item in Clipboard
Review
Epratuzumab for systemic lupus erythematosus
Lupus.
2013 Apr.
Abstract
Epratuzumab (EMab, UCB, Immunomedics) is a humanized monoclonal antibody targeting CD22 that is being studied in clinical trials for patients with a variety of rheumatic and hematologic conditions, including systemic lupus erythematosus (SLE). An overview of its mechanism of action is followed by a summary of completed lupus studies, and a preview of studies in progress. The agent clearly has anti-inflammatory activity and is a potentially useful agent in the management of autoimmune disorders.
Similar articles
-
CD22 and autoimmune disease.Int Rev Immunol. 2012 Oct;31(5):363-78. doi: 10.3109/08830185.2012.709890. Int Rev Immunol. 2012. PMID: 23083346 Review.
-
The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus.Autoimmun Rev. 2015 Dec;14(12):1079-86. doi: 10.1016/j.autrev.2015.07.013. Epub 2015 Jul 23. Autoimmun Rev. 2015. PMID: 26212727 Review.
-
Epratuzumab for the treatment of systemic lupus erythematosus.Expert Rev Clin Immunol. 2018 Apr;14(4):245-258. doi: 10.1080/1744666X.2018.1450141. Epub 2018 Mar 20. Expert Rev Clin Immunol. 2018. PMID: 29542345 Review.
-
Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.Blood. 2013 Oct 24;122(17):3020-9. doi: 10.1182/blood-2012-12-473744. Epub 2013 Jul 2. Blood. 2013. PMID: 23821660
-
Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again.Arthritis Res Ther. 2006;8(3):108. doi: 10.1186/ar1967. Epub 2006 May 15. Arthritis Res Ther. 2006. PMID: 16732895 Free PMC article.
Cited by
-
B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice.Front Med (Lausanne). 2020 Jul 9;7:316. doi: 10.3389/fmed.2020.00316. eCollection 2020. Front Med (Lausanne). 2020. PMID: 32754605 Free PMC article. Review.
-
Human CD22 Inhibits Murine B Cell Receptor Activation in a Human CD22 Transgenic Mouse Model.J Immunol. 2017 Nov 1;199(9):3116-3128. doi: 10.4049/jimmunol.1700898. Epub 2017 Sep 29. J Immunol. 2017. PMID: 28972089 Free PMC article.
-
Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2.Pediatr Blood Cancer. 2015 Jul;62(7):1171-5. doi: 10.1002/pbc.25454. Epub 2015 Mar 2. Pediatr Blood Cancer. 2015. PMID: 25732247 Free PMC article. Clinical Trial.
-
CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity.Front Immunol. 2018 Sep 28;9:2235. doi: 10.3389/fimmu.2018.02235. eCollection 2018. Front Immunol. 2018. PMID: 30323814 Free PMC article. Review.
-
Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus.Drug Des Devel Ther. 2014 Nov 17;8:2303-10. doi: 10.2147/DDDT.S49778. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 25429203 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
